Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.48 |
| ▸ | P4HB | P07237 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CCR6 | P51684 | 1/20 | 0.40 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6950153 | 0.93 | HDAC10 (0.43) | NOTUMP4HBHDAC10HDAC6KDM4A | |
| SCHEMBL12230860 | 0.90 | NOTUM (0.45) | NOTUMP4HBHDAC10HDAC6KDM4A | |
| SCHEMBL28994237 | 0.89 | HDAC10 (0.40) | NOTUMP4HBHDAC10HDAC6KDM4A | |
| SCHEMBL2446141 | 0.88 | EPHX2 (0.46) | HDAC10HDAC6KDM4ABRD4NAMPT | |
| SCHEMBL15862086 | 0.88 | KDM4A (0.44) | NOTUMHDAC10HDAC6KDM4ABRD4 | |
| SCHEMBL28994250 | 0.86 | HDAC1 (0.41) | NOTUMP4HBHDAC10HDAC6KDM4A | |
| SCHEMBL1495846 | 0.85 | EPHX2 (0.49) | NOTUMHDAC10HDAC6KDM4ABRD4 | |
| SCHEMBL12231188 | 0.84 | EPHX2 (0.50) | HDAC10HDAC6KDM4AALDH1A1LMNA | |
| SCHEMBL1495955 | 0.84 | EPHX2 (0.50) | NOTUMKDM4A | |
| SCHEMBL12231412 | 0.84 | MAPT (0.47) | NOTUMHDAC10HDAC6KDM4ABRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3104703-B1 | FACTOR XIA INHIBITORS | MERCK SHARP & DOHME (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-3104703-B1 | FACTOR XIA INHIBITORS | MERCK SHARP & DOHME (US) | 2020-11-18 | — | — | EP | disclosed |
| US-9944643-B2 | Factor XIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160376272-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-29 | — | — | US | disclosed |
| EP-3104703-A1 | FACTOR XIA INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-12-21 | — | — | EP | disclosed |
| WO-2015123093-A1 | FACTOR XIA INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-08-20 | — | — | WO | disclosed |
| WO-2015123093-A1 | FACTOR XIA INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-08-20 | — | — | WO | disclosed |
| US-8912209-B2 | Rock inhibitors | AMAKEM NV (BE) | 2014-12-16 | — | — | US | disclosed |
| US-8815873-B2 | Heterocyclic amides as rock inhibitors | AMAKEM NV (BE) | 2014-08-26 | — | — | US | disclosed |
| US-20130252975-A1 | NOVEL ROCK INHIBITORS | AMAKEM NV (BE) | 2013-09-26 | — | — | US | disclosed |
| EP-2626348-A1 | Heterocyclic amides as rock inhibitors | Amakem NV (BE) | 2013-08-14 | — | — | EP | disclosed |
| EP-2542528-B1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | AMAKEM NV (BE) | 2013-06-19 | — | — | EP | disclosed |
| EP-2542528-A1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | Amakem NV (BE) | 2013-01-09 | — | — | EP | disclosed |
| US-20120322801-A1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | AMAKEM NV (BE) | 2012-12-20 | — | — | US | disclosed |
| WO-2011107608-A1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | AMAKEM NV (BE) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322801-A1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | ROCK1, ROCK2, CIT | NOTUM 1592/4885P4HB 4011/4885HDAC10 754/4885 |
| US-20160376272-A1 | FACTOR XIa INHIBITORS | F11, SERPINC1, TFPI | NOTUM 757/4885P4HB 1912/4885HDAC10 994/4885 |
| US-20130252975-A1 | NOVEL ROCK INHIBITORS | ROCK1, ROCK2, CIT | NOTUM 2417/4885P4HB 4678/4885HDAC10 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.